Effective sample size estimation for a mechanical ventilation trial through Monte-Carlo simulation: Length of mechanical ventilation and Ventilator Free Days by Morton, S.E. et al.
Effective Sample Size Estimation for a Mechanical Ventilation Trial Through Monte-
Carlo Simulation: Length of Mechanical Ventilation and Ventilation Free Days. 
 
Sophie Morton a,*   sophie.morton@pg.canterbury.ac.nz  
Yeong Shiong Chiew a,1  chiew.yeong.shiong@monash.edu  
Christopher Pretty a   chris.pretty@canterbury.ac.nz 
Elena Moltchanova b   elena.moltchanova@canterbury.ac.nz 
Carl Scarrott b    carl.scarrott@canterbury.ac.nz 
Daniel Redmond a   daniel.redmond@pg.canterbury.ac.nz 
Geoffrey M Shaw c   geoff.shaw@cdhb.health.nz 
J. Geoffrey Chase a    geoff.chase@canterbury.ac.nz 
 
 
a Department of Mechanical Engineering, University of Canterbury, Christchurch, New 
Zealand 
b School of Mathematics and Statistics, University of Canterbury, Christchurch, New Zealand 
c Intensive Care Unit, Christchurch Hospital, Christchurch, New Zealand 
* Corresponding author 
1 Present address: Malaysia School of Engineering, Monash University Sunway Malaysia  
 
 
Keywords: Statistical significance, mechanical ventilation, Monte Carlo methods, randomised 
control trials, outcome metrics, ventilator free days  
 
 
Abbreviations Used:  
ARDS  Acute Respiratory Distress Syndrome 
ICU  Intensive Care Unit 
KS-test Kolmogorov-Smirnov Test    
LoMV  Length of Mechanical Ventilation 
LoMV-28 Length of Mechanical Ventilation - 28 Days 
MV  Mechanical Ventilation 
RCT  Randomised Control Trial 
RS-test Wilcoxon-Ranksum Test 




Randomised control trials (RCTs) have sought to seek to improve mechanical ventilation (MV) 
treatment. However, few RCTs to date have shown clinical significance. It is hypothesised that 
aside from effective treatment, the outcome metrics and sample sizes of the trial also affect the 
significance, and thus impact trial design.  
 
In this study, a Monte-Carlo simulation method is developed and used to investigate several 
outcome metrics of MV treatment, including 1) Length of Mechanical Ventilation (LoMV); 2) 
ventilator free days (VFD); and 3) LoMV-28. In addition, it investigates the impact of imposing 
clinically relevant exclusion criteria on study power to enable better design for significance. 
Data from invasively ventilated patients from a single intensive care unit were used in this 
analysis to demonstrate the method.  
 
Use of LoMV as an outcome metric found that 160 patients/arm were required to reach 80% 
power with a clinically expected intervention difference of 25% LoMV if clinically relevant 
exclusion criteria are applied to the cohort, but 400 patients/arm if they are not. However, 130 
patients/arm would be required for the same statistical significance at the same intervention 
difference if VFD is used. 
 
A Monte-Carlo simulation approach using local cohort data combined with objective patient 
selection criteria can yield better design of ventilation studies to desired power and 
significance, but with fewer patients per arm than traditional trial design methods, which in 
turn reduces patient risk. Use of outcome metrics, such as VFD should be used when there is 
also expected to be a difference in mortality between the two cohorts. Finally, the non-
parametric approach taken is readily generalisable to a range of trial types where outcome data 
is similarly skewed.  
1. Introduction 
Mechanical Ventilation is a core intensive care therapy for patients suffering from respiratory 
failure or acute respiratory distress syndrome (ARDS) [1]. While it is a relatively 
straightforward treatment, optimising mechanical ventilation without causing damage to the 
lung is complex in practice. A range of randomised control trials (RCTs) have been carried out 
to assess methods of improving patient MV care. However, many have had non-significant 
findings [2–5], and the field remains uninformed about consistent action that might improve 
outcomes. 
 
Respiratory failure is often a secondary symptom from a range of diseases, many causing lung 
damage that is mixed in effect and severity [6]. Thus, the generalised treatment proposed in 
some RCTs may not provide the best possible treatment for all patient types. In addition, 
insignificant RCT results may also be partly due to difficulty in determining the efficacy of 
mechanical ventilation therapy. Aside from patient mortality, other metrics used to assess the 
quality of mechanical ventilation treatment include cardiopulmonary and haemodynamic 
responses, patients’ physiological or acuity scores, and patients’ ventilator dependency such as 
length of mechanical ventilation (LoMV) and ventilator free days (VFDs). However, all these 
metrics have limitations. 
 
LoMV or VFD are the two most common metrics that were used to assess MV efficacy. These 
metrics consider patient ventilator dependency and how early patients are weaned from the 
ventilator along with the mortality rate for the cohort [7]. They also assess the economic impact, 
as ventilator dependency is associated with higher cost [8].  
 
For a clinical trial to be successful, it must have both useful results and statistical significance 
[9]. While a trial may have useful clinical results, it is unable to make a meaningful statement 
without sufficient statistical significance or ‘power’. Thus, determining the necessary effective 
trial sample size to reach a sufficient power is critical. Table 1 shows a range of mechanical 
ventilation RCTs that use LoMV or VFD as one of their outcome metrics [2–5,10–13]. These 
studies ranged in size from 70-2300 patients, with only two able to reach a statistical 
significance of p<0.05. 
 





Groups (Number of patient)  
LoMV or VFD 
(in mean ± standard deviation or  
median [interquartile range]) 
p-
value 
ARDSNet [5]  861 VFD 
 
Low Vt+ (432) 
12±11 
High Vt (429) 
10±11 
0.0070 





Higher PEEP (276) 
13.8±10.6 
0.5000 









LOVS [3] 983 LoMV Control (507) 
10 [6-16] 























Sedation Study  
[11] 
113 VFD Control (58) 
18.0 [0-24.1] 




When clinical significance was not found, it was often due to ineffective treatment or inability 
to effectively treat all patients. However, high levels of patient variability as well as insufficient 
sample sizes can significantly impact the ability of a clinical study to achieve significance 
[15,16]. In an earlier study by Chiew et al [17], it was also noted that the commonly used 
sample size estimation methods for a powered study [18] were not feasible for LoMV clinical 
data that were heavily skewed with a very long upper tail. Thus, it is not possible to truly assess 
whether trial design or numbers, or trial inefficacy are the course of failure. Hence, a 
simulation-based method using retrospective clinical cohort data may provide a better 
estimation of a well-powered sample size for a desired outcome metric and patient cohort [19]. 
 
This study presents a Monte-Carlo simulation-based method to estimate sample sizes for a 
powered and significant RCT for a range of outcome metrics relating to ventilator dependency. 
The outcome metrics investigated in this study were LoMV, VFD and a modified LoMV. A 
case study for determining the sample sizes of a planned RCT is also presented, where patient 
selection criteria are also simulated to replicate the planned RCT as closely as possible [20]. 
Overall this study presents a non-parametric simulation based method that is readily 
generalisable for trial design, and presents it in terms of a sample size study design involving 
LoMV and VFD, their potential limitations, including a case example which also demonstrates 
how this method can effectively pre-test a cohort when designing the trial. 
 
    
2. Methods 
2.1. Sample size analysis metric 
Three outcome metrics for sample size estimation were investigated: 1) Length of mechanical 
ventilation (LoMV); 2) Ventilation free days in 28 days (VFD) [7]; and 3) Length of mechanical 
ventilation within 28 days (LoMV-28). VFD and LoMV-28 are modified LoMV distributions that 
also include mortality information where deceased patients have 0 VFD or 28 days of LoMV. 
Table 2 shows a more detailed description of each outcome metric used in this study. 
 
Table 2: Outcome metrics to be used in study 
1. LoMV: The total duration of mechanical ventilation. 
2. VFD: The number of days free of MV within a 28 day period. VFD is defined 
by [7] as:  
 VFD = 0: if the patient dies before 28 days 
 VFD = (28 – LoMV): if the patient is successfully weaned from 
MV within 28 days. 
 VFD = 0: if the patients requires MV for 28 days or more 
3. LoMV-28: Length of MV within 28 days, where: 
 LoMV-28 = 28: if the patient dies before 28 days 
 LoMV-28 = LoMV: if the patient is successfully weaned from 
MV within 28 days 
 LoMV-28 = 28: if the patients required MV for 28 days or more.  
 
 
2.2. Retrospective patient cohort data (Cohort A) 
Retrospective data from 5176 patients admitted to the Christchurch Hospital Intensive Care Unit 
(ICU) from 2011 to 2014 was considered in this study. All APACHE III diagnostic codes, ICU 
mortality and length of mechanical ventilation (LoMV) were recorded. Of this number, 3896 
(75%) patients required MV therapy and 3383 (63%) received invasive ventilation either through 
tracheotomy or intubation.  
In this study, only patients who were invasively ventilated are considered, which is the largest 
possible cohort and delineated Cohort A in this study. The mean LoMV is 2.95 ± 6.50 days 
(median = 0.73 [IQR: 0.24 – 2.48]). The detailed patient distribution for this cohort and their 
corresponding LoMV and mortality distribution can be found in Appendix A, Tables A1 to A3. 
The description of APACHE III diagnostic codes is included in Appendix B. 
 
2.3. Simulating realistic clinical trial cohorts (Cohort B) 
Not all invasively ventilated patients may benefit from optimised MV. For example, some patient 
groups receive MV only for brief post-surgical periods. Hence, they would not be part of such a 
trial. The difficulty is that exclusion criteria in many trials are subjective and thus can add 
variability and unintended dimensionality to the study, affecting the potential outcome in ways 
not included in the study design. 
 
Using Monte-Carlo simulation, an objective patient cohort can be created and simulated from 
Cohort A. This objective cohort (Cohort B) aims to capture the realistic characteristics of a patient 
cohort expected to be used in a planned clinical trial. Objective patient selection is enabled using 
the APACHE III diagnostic code to simulate the actual clinical trial inclusion and exclusion 
criteria. Many of these criteria have been used in prior studies [2–5,10–12], and objective criteria 
for all exclusions would ensure a more robust design and implementation.  
 
The exclusion criteria typically used are listed below and the studies they are used in are 
referenced. These criteria include: 
 
1. Patients who are likely to be discontinued from MV within 24 hours [10,11];  
2. Patients with raised intracranial pressure [2–5,10–12];  
3. Patients who have significant weakness from any neurological disease [2–5,10]; 
4. Patients who have asthma as the primary presenting condition, or a history of 
significant chronic obstructive pulmonary disease [2–5].  
 
In this study, a sample of clinical inclusion and exclusion criteria for a randomised controlled trial 
is used (ANZCTR number: ACTRN12614001069640). Inclusion criteria are set to target every 
patient that is eligible for the study (Cohort A). The exclusion criteria are chosen based on the 
clinical implication that these patients may not benefit from a MV intervention, or could be 
harmed in some cases – as listed above.  
 
In this study, the objective cohort (Cohort B) was established by excluding all patients under 
APACHE III diagnostic codes as shown in Appendix Table A4, which are relevant to the 4 main 
criteria typically used and listed above. The use of diagnostic codes avoids also subjective choices 
in both simulation and implementation, where such subjectivity is difficult to model and induces 
unintended variability from what might actually occur. It could also be easily and objectively 
implemented in a real trial, which would better ensure that the trial design and the actual study 
matched.  
 
Thus, the following specific APACHE III diagnostic codes were also excluded in implementing 
the typical exclusion criteria listed previously:  
 
 206  - Chronic obstructive pulmonary disease 
 209  - Asthma 
 400  - Neurological non-operative  
 601  - Head trauma with or without multi trauma 
 604  - Multi trauma with spinal injury 
 605  - Isolated cervical spine injury 
 1500  - Neurological post-operative 
 1601  - Post operation patients: head trauma with or without multi trauma 
 1604  - Post operation patients: Multi trauma with spinal injury 
 1605  - Post operation patients: isolated cervical spine injury  
 
This approach makes the criteria objective and easy to implement both in simulation and in a 
clinical trial. After imposing the exclusion criteria, the number of patients eligible for the study is 
reduced to 974 (18.8% of total patients admitted to ICU or 28.8% of patients requiring invasive 
MV). This cohort is denoted as Cohort B. A detailed comparison of the actual trial exclusion 
criteria and simulation method is shown in Appendix Table B1. 
 
2.4. Sample size determination using Monte-Carlo simulation 
A Monte-Carlo simulation was performed to determine the power of the study at a range of sample 
sizes. This simulation allows a range of intervention effects to be simulated, and the corresponding 
sample sizes required to detect the significance at a power, to be calculated. A 10,000 iteration 
Monte-Carlo simulation was run over the data to determine the required sample size for each arm 
of the study to achieve 80% power. In this study, the sample sizes for Cohort A and Cohort B with 
different characteristics were examined.  
 
Both double-sided and single-sided log-normal Student t-test (t-test), Wilcoxon Rank-Sum (RS-
test) and a Kolmogorov-Smirnov test (KS-test) were used for significance testing of the difference 
in mean and other distribution characteristics (median and variability). All simulations were 
performed using MATLAB [21]. 
 
The hierarchical steps followed to carry out the Monte-Carlo design analysis are outlined in Table 
3. The change into VFD and LoMV-28 metrics is carried out after the LoMV difference has been 
imposed on the intervention group (Step 3) and before the statistical testing (Step 4). 
 
Table 3: Steps followed in Monte Carlo Simulation 
 Step Description  Tested Group 
1. Patient 
Cohorts 
 Select a patient cohort  
1) Cohort A includes all invasively 
ventilated patients or  
2) Cohort B is created from Cohort A by 
imposing exclusion criteria.  
 Cohort A 




 Randomly select patients from the patient 
cohort and assign each patients to a 
treatment group. 1) Control group or 2) 
Intervention group. 
 Patient is selected with replacement. 
 Various sample size of each treatment 
group is tested. 
 Total sample size N= 
100, 110, 120… 
2000 patients  
3. Difference 
in LoMV 
 Impose an intervention effect to simulate 
differences in LoMV between the two 
groups. 
 The LoMV in Intervention group is reduced 
by the chosen percentage. 
 LoMV intervention = LoMV patient × 
(100% -Percentage reduction) 
 The difference in LoMV ranges from 10 to 
25% of total LoMV. 
 Difference of LoMV 





 Calculation of VFD and LoMV-28 using 
given LoMV. 
 Cohort A 
 Cohort B 
5. Statistical 
Test 
 Perform statistical test comparing the 
metrics (LoMV, VFD, LoMV-28) between 
two groups. 
 Using parametric and non-parametric tests. 
 A p-value < 0.05 indicates that LoMV for 
intervention group is significantly different 
from control group. 
 Student t-test (log 
scale) 
 RS test 
 KS test 
6. Power 
Analysis 
 Each Monte-Carlo simulation iteration will 
generate a p-value for each statistical test.  
 For a given sample size and significance 
level α, statistical power is evaluated as the 
proportion of iterations for which p < α. 
 E.g. for 10000 
Monte-Carlo 
iterations, if p < α for 
84% (8400 
iterations), Power = 
0.84. 
 
2.5. Baseline distributions of each outcome metric 
Figure 1 shows a distribution of the LOMV, VFD and LOMV-28 distribution for 10,000 cohorts 
of 100 patients selected from Cohort A and Cohort B prior to implementing an intervention effect. 
Patient selection was iterated 10,000 times using random selection with replacement (Table 3, 
Step 2) to create the boxplots. As can be seen, both the LoMV and LoMV-28 cohorts have 
significantly skewed log-normal distributions, whereas VFD shows a reverse log-normal 
distribution that is highly skewed towards 28 days.  
 
The distribution spikes at the start of the VFD, and end of the LoMV-28 plots are due to the impact 
of mortality data on these metrics. This clearly shows how any change in mortality due to an 
intervention can have a further significant effect on the distribution shape. Finally, the LoMV-28 
and VFD metrics are also not log-normal given these spikes, which would likely cause further 
issues when using a trial design method based on a normal distribution assumption, even if the 
data was logged. Consequently, use of sample size estimation methods that require a Gaussian 
distribution, which is the common approach, would not have been appropriate for these outcome 
metrics [17,18], and thus non-parametric statistics and Monte Carlo analysis, as proposed, should 


















Figure 1: Outcome metric distributions for sample size of 100 patients. 
2.6. Analyses 
Each cohort size for N = 100 – 2000 with a 10 patient step size are analysed as follows: 
1. Cohort A (LoMV, VFD, LoMV-28) 
2. Cohort B (LoMV, VFD, LoMV-28) 
Analyses 1 and 2 use a two-tailed test. Two-tailed tests can separate whether the intervention 
yields a better or worse outcome. A one-tailed test assumes the intervention is better or not 
better, but cannot show it is worse. A one-tailed test at p<0.025 is considered equivalent to a 
two-tailed test at p<0.05. However, clinically, an intervention that is not better is potentially 
enough of an answer, as clinicians seek better treatment. Therefore, the impact of single-tail 
testing in this approach was also considered for: 
3. Cohort B (single vs double-tailed tests) for LoMV, VFD, LoMV-28. 
Finally, all tests in 1-3 assume equivalent mortality as simulated. However, a good intervention 
might be expected to reduce mortality, which in turn affects VFD and LoMV-28. This aspect was 
also simulated, by randomly selecting patients to have their mortality changed in the intervention 
cohort, and repeating Analysis #2: 
4. Cohort B (5% and 10% mortality differential) for the mortality affected VFD, LoMV-28 
metrics. 
These four analyses clearly delineate the impact on trial design and trial size, using such nonlinear 
distributions and metrics, for explicit exclusion criteria in cohort selection (Analysis #1 vs 
Analysis #2), statistical test used (Analysis #3), and the impact of mortality when using mortality 
affected metrics (Analysis #4). 
 
 
2.7 Overall Impact of Method, Cohorts and Analyses: 
The struggle that the design of many ventilation trials face is the excessive dimensionality of 
patient factors (diagnosis, age, sex) and MV care factors (how they are treated, and thus the size 
of the intervention effect). The key to this method and trial design approach is that it collapses 
that dimensionality in two ways. First, the objective exclusion criteria, eliminate unintended 
subjectivity and patient dimensions, where subjectively patients may be either included or 
excluded, creating variability between the trial cohort and the intended target cohort who might 
benefit. Second, it does so through the use of repeated simulation, thus covering all possible or 
likely cohort outcomes, where the use of 4-years of data from the trial unit provides a final means 
of reducing potential unintended variability in this model-based approach. Thus, the use of 
objective inclusion and exclusion in-silico criteria reduces a lot of dimensionality and uncertainty 
that would otherwise occur. 
 
The overall non-parametric simulation methods and design approach was selected as it would be 
feasible in a clinical trial. The objectivity implemented in a manner where it can be used in the 
actual trial ensures the desired lower dimensionality is preserved. In turn, this outcome provides 
an increased chance of reaching significance through better control of the trial design and the 
actual trial so that the trial design is a far better match for what occurs in implementation, 




3.1. Sample size estimation for each metric (Analyses #1 and #2) 
Graphical results for sample size estimation with a 25% difference in LoMV between control and 
intervention groups are shown in Figure 2. The X-axis shows the samples size and the Y-axis 
shows the corresponding power obtained through the 10000 iteration Monte-Carlo simulation at 
each sample size. Cohort A which included all invasively ventilated patients had a much lower 
power compared to Cohort B. Due to the negatively skewed distribution of the VFD metric as 
shown in Figure 1, a log-transformed student t-test was not suitable for the significance testing. 






















Figure 2. Results of Monte Carlo simulation for 25% LoMV difference 
The power analysis was carried out for each metric at LoMV differences (ΔLoMV) of 10%, 15%, 
20% and 25% and the estimated sample sizes per trial arm are shown in Table 4. These effect 
sizes are realistic based on the trials summarised in Table 1. 
 
Table 4: Estimated sample sizes per trial arm for LoMV outcome metric sizes of 10-25% 
in 5% increments, for both Cohorts A and B, using all 3 statistical tests. 
ΔLoMV Wilcoxon Ranksum Kolmogorov-Smirnov 
 
Student T-Test (log 
scale) 
Cohort A B  A B A B 
10% 2000+ 1350 2000+ 750 2000+ 2000+ 
15% 1340 530 1530 370 1330 670 
20% 670 270 850 240 670 310 
25% 400 160 530 160 390 180 
ΔVFD  
10% 2000+ 2000+ 2000+ 850 
T-Tests were not able to 
be used for the VFD 
metric 
15% 2000+ 2000+ 1800 500 
20% 1460 700 1030 330 
25% 790 390 650 220 
ΔLoMV-28  
10% 2000+ 2000+ 2000+ 860 2000+ 2000+ 
15% 2000+ 2000+ 860 480+ 2000+ 2000+ 
20% 700 700 330 330 1160 1160 
25% 490 380 510 230 490 540 
 
Transferring the input parameter uncertainties to ranges is achievable. The uncertainty in patient 
types and which patients might arrive at a given trial period was covered parametrically by the 
dimensions Ncohort, Δeffect and a reduced mortality on the VFD and LoMV-28 metrics, as well as 
by using 4-years of patient data from the trial center. Thus, the resulting, Monte Carlo range of p-
values from each Monte Carlo run yields the power at a significance level of 0.05, as seen in 
Figure 3 and Table 4. For clarity, Figure 2 demonstrates the ability of this method to also show 
the range of p-values that dictate whether or not the sample size can achieve a power of 80%. The 
box and whisker plots show the results from a 25% LoMV difference, as in Figure 1, but with the 
full range of Monte Carlo run results, where Cohort B has the objective trial exclusion criteria 
applied. 
Cohort A Cohort B 
  
Figure 3: Results of each Monte Carlo simulation for 25% LoMV difference in box and 
whiskers format for both Cohorts A and B, with p < 0.05 shown. The percentage of results 
below p = 0.05 indicates the power at that sample size. 
 
3.2. Single vs double-tailed tests (Analysis #3) 
Single (upper) tailed Wilcoxon Rank-Sum and t-tests were carried out on each metric with a set 
significant level of 0.05 to assess whether this had an impact on the results. At a LoMV 
difference of 25%, there is no difference in the required sample size in LoMV and LoMV-28, as 
shown in Table 5. However, for the VFD metric, a significant reduction of required sample size 




Table 5: Sample size comparison between single-tailed and double-tailed statistical tests 
for LoMV, LoMV-28 and VFD when the intervention effect is 25% reduction in LoMV 













RS-Test 160 160 290 390 380 380 
KS-Test  160 160 170 230 230 230 
Log T-Test 180 180 N/A N/A 550 540 
 
3.3. Impact of mortality difference (Analysis #4)  
Schoenfeld et al [7] hypothesised that using VFD to determine intervention differences would 
require a much higher sample size than LoMV if there was not a significant difference in mortality 
rates. To this end, concomitant mortality rate reductions of 5% and 10% was simulated in the 
intervention cohort for the LoMV-28 and VFD metrics [2]. The sample sizes for a 25% LoMV 
difference and 5 to 10% of mortality rate difference for the Wilcoxon-Ranksum and Kolmogorov-
Smirnov analyses are shown in Table 6. 
 
Table 6: Impact of simulating a mortality differential between control and intervention 
cohorts for VFD and LoMV-28 outcome metrics. 
 






RS-Test KS-Test RS-Test KS-Test RS-Test KS-Test 
LoMV-28 
380 230 190 190 110 140 
VFD 
280 220 130 130 90 100 
 
 
As can be seen, the sample size required to reach 80% power is significantly reduced if a mortality 
differential of 5% occurs between each cohort. Such an improvement is reasonably possible for a 
targeted cohort receiving better care. To capitalise on these findings, it is recommended that the 





4.1. Impact of intervention effect and exclusion criteria on results 
The Monte-Carlo simulation based design method was able to estimate the sample size required 
for a clinical trial to detect a significant difference with set power. It was found that when the 
intervention effect is small at 10%, much larger sample sizes of more than 2000 patients per 
trial arm are required as compared to larger intervention effects, as expected. This larger sample 
size from the typical design method is due to the skewed and highly variable distribution of 
ventilation duration of the cohort, and is indicative of the range of patients’ underlying 
conditions that require mechanical ventilation. Importantly, these distributions in Figure 1 are 
typical and do not match the assumptions made by typical design tools. 
 
When the exclusion criteria are implemented in the simulation, the required sample sizes per 
arm at the same intervention effect, is further reduced. From Figure 1, it is clear that if Cohort 
A was considered as the trial cohort, the sample size required for clinical significance and a 
well-powered study is much higher compared to targeting a specific patient cohort (Cohort B). 
This result shows that targeting a specific cohort through implementing objective and easily 
defined inclusion and exclusion criteria available at patient admission can result in a ‘narrower’ 
metric distribution, which is important. Thus, a clinical trial that aimed to reduce LoMV, or 
increase VFD, should be designed to target specific patient groups who are likely to benefit 
from the treatment and whose distribution of patient-specific LoMV is amended to seeing a 
change for reasonable sample size [17]. 
 
Finally, and importantly, trial sizes also impact on patient risk. A trial with equipoise in its 
hypothesis includes the risk of the intervention possibly having a negative effect on patient 
outcome. Thus, the fewer the number of patients in the trial design that are needed to achieve 
significance and power, achieved here with a non-parametric Monte Carlo simulation design 
approach, the lesser the risk to patients in determining the impact and safety of the intervention. 
 
4.2. Impact of different outcome metrics and intervention effect 
Sample sizes for different outcome metrics were examined in this study. The LoMV metric 
was found to have the smallest sample size required to achieve significance with 80% power 
compared to the other 2 metrics. This was attained with 160 patients required per trial arm for 
a 25% LoMV reduction difference in Cohort B. However, at a difference of 20% this value 
increases to 270 patients per arm. 15% and 10% differences see a rise to 1000 patients per arm 
for an 80% powered study. This finding also shows the perils of these outcome metrics and one 
possible reason behind non-significant RCTs aside from non-effective clinical interventions. 
Specifically, if a large intervention effect, which is difficult to achieve, cannot be obtained trial 
sizes grow rapidly along with the likelihood of other risks to the trial. 
 
Both the VFD and LoMV-28 outcome metrics were studied with the hypothesis that the 
inclusion of mortality would affect the power of the study. The VFD metric was specifically 
designed with the intention that a new treatment that either reduced the length of ventilation, 
or mortality, would be more likely to show a significant difference in a trial [7]. However, this 
simulation does not include any changes in mortality and hence the effect is minimal and both 
metrics have led to a lower powered study than the standard LoMV outcome. It is expected 
that the discrepancy in the t-test results for the LoMV-28 metric is due to the change in 
distribution shape due to the peak at 28 days. This obstructs the ability of the statistical testing 
method to detect a significant difference. 
4.3. Impact of different statistical tests 
Incorrect assumptions about the distribution of data can result in an inconclusive and under-
powered study [15]. A two sample unpaired t-test requires data with a Gaussian distribution. 
The log-normal distribution of the LoMV and LoMV-28 allowed a log-transformed t-test to be 
carried out on the data. This distribution shape was verified by the similar results from the 
Wilcoxon Rank-Sum analysis. The negatively skewed VFD metric did not meet the Gaussian 
distribution assumption for a t-test, even when log-transformed.  
 
The impact of using a single-tailed test with a significance level of 0.025 was assessed for the 
LoMV and LoMV-28 outcome metrics and found to be minimal. However, it showed a 
significant improvement in the study power for the VFD metric in Table 5.  
 
It is possible to choose the test with the lowest sample size using this method. This has often 
been the case for most clinical trials. The criteria for choosing one statistical method over 
another has often been due to statistical ‘correctness’, a limitation of resources for the trial 
favouring lower numbers, or due to ethics committee or independent statistician requirements. 
If it is known that a treatment is not improving prognoses, it is not ethical to continue with it. 
 
Often with skewed data sets, such as LoMV, it is preferable to use a non-parametric statistical 
test. Hence, of the three tests used in this study (Kolmogorov-Smirnov, Wilcoxon Ranksum 
and (log) Student T-Test), only the T-Test assumes a distribution., which is then log corrected 
Ideally, either of the two non-parametric tests would be used, where Kolmogorov-Smirnov is 
more sensitive to differences in distribution spread, while Wilcoxon Ranksum is more sensitive 
to differences in the data set median. Which test should be used would depend on what a given 
trial is aiming to achieve. 
 
4.4. Absolute vs percentage decrease in intervention effects for VFD outcome metric 
As shown in Tables 5 and 6, the VFD outcome metric displayed a considerably lower power 
than LoMV-28. This result was unexpected as the distributions of each metric are mirrored, 
and non-parametric tests were used. The inconsistency is due to the use of percentage LoMV 
reductions. Percentage reductions imply less change for shorter stay patients, which is 
clinically reasonable vs an absolute change that has lesser impact for longer stay patients. Table 
7 demonstrates the discrepancy in percentage changes for an initial LoMV of 5 days, with 
intervention of 20% LoMV.  
 
Table 7: Differences between absolute and percentage reductions, for initial LoMV of 5 
days 





LoMV 5 4 20% 
LoMV-28 5 4 20% 
VFD 28-5 = 23 28-4 = 24 4% 
 
In this case, the VFD metric with a typically seen LoMV of ~5 days means a large change in 
LoMV and thus LoMV-28 as a percentage is a relatively small change in VFD. At LoMV = 14 
days the effect would be equal, and over 14 days the situation would reverse with greater effect 
for VFD and an easier ability to detect change in this metric. This latter case is shown in Table 
8 with an initial LoMV of 20 days, and a percentage reduction of 20%.  
 
Hence, the choice of LoMV-28 or VFD should depend primarily on the given initial 
distribution, and this outcome would apply more generally to other trial design approaches with 
similar metrics. In addition, Using LoMV as the root outcome to test in simulation is important, 
as well as knowing the exact distribution. This Monte-Carlo approach can do this, unlike other 
commonly used methods. 
 
Table 8: Differences between absolute and percentage reductions, for initial LoMV of 20 
days 





LoMV 20 16 20% 
LoMV-28 20 16 20% 
VFD 28-20 = 8 28-16 = 12 33% 
 
 
4.5. Statistical significance and power 
A significant problem in many trials is concentrating on the clinical results, while neglecting 
the statistical significance [9]. Conducting a power analysis allows the probability of correctly 
detecting a difference between the control and intervention groups to be determined [9]. This 
process is complicated when highly variable data that is not normally distributed is being 
analysed. This analysis used Monte Carlo simulation, combined with clinically relevant 
exclusion criteria as a viable method of determining the power of a study that uses a primary 
outcome metric of LoMV. 
 
If the specific RCT assessed in this paper solely analysed LoMV, 160 patients in each arm 
would be sufficient to achieve a statistically significant result with 80% power and an 
intervention difference of 25%. However, using an outcome metric that also considers 
mortality data, such as VFD or LoMV-28, could be beneficial if there is a mortality difference 
between each cohort. Using the VFD metric with the same intervention effect can reduce the 
number of patients required to 130/arm with a mortality differential of 5%. 
 
Due to the high variability and skewed distribution of LoMV data, it is a difficult metric to use 
to assess the power of a clinical trial [15]. However, it remains one of the most effective 
methods of determining the efficacy of MV treatment. In addition due to the high cost of 
ventilator therapy, reductions in ventilator duration have significant economic impacts for care 
units and hospitals [8]. 
 
4.6. Limitations 
4.6.1. Use of data from a specific ICU  
The study was undertaken with the assumption that the data used in the simulation was 
indicative of that which would be used in the RCT. However, use of LoMV distribution data 
from a single, specific ICU may mean that the results are not universally applicable, and only 
able to be used in those with similar characteristics [15]. Nevertheless, the approach followed 
in this study is general enough to be able to be repeated and utilised for most centres. If 
information on LoMV distribution is required, then a small and centre-specific pilot study 
could be carried out. In the case of a multi-centre study, information from multiple centres 
should be used.  
5. Conclusions 
In this study, a Monte-Carlo simulation method was able to effectively estimate the sample 
sizes required for a clinical trial that consists of a highly variable and skewed outcome metric, 
such as LoMV. The effect of using LoMV, VFD or LoMV-28 was assessed, along with the 
impact of imposing clinically relevant exclusion criteria. Higher sample sizes for a powered 
study is required for VFD, as the intervention effect converting from LoMV to VFD is 
different. However, the use of VFD could be improve if additional mortality rate difference 
was included. 
 
For a clinical trial, the shape of LoMV distribution is critical, and use of exclusion criteria to 
target patient groups which may benefit from this intervention is useful. Assessment of ΔLoMV 
in response to treatment should be considered to avoid an under-powered study. Monte-Carlo 
simulation, combined with objective patient selection criteria provides better design of 
ventilation studies. Finally, the overall approach used here is readily generalisable to most trials 
where the outcome measures are based on a lognormal or otherwise skewed data set, such as 
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Table A1: Patient number and distribution 
 Patient Number   
 2011 2012 2013 2014 Total 
All patients 1279 1284 1344 1269 5176 
MV 1004 953 963 977 3897 
Invasive MV 878 825 830 850 3383 
 
Table A2: Patient LoMV distribution 
 LoMV distribution (Days) 
mean ± std, [median, IQR] 
 
























Table A3: Mortality LoMV distribution 
 ICU Mortality rate (%)  
 2011 2012 2013 2014 2011-2014 
All patient 8.68% 11.99% 8.93% 10.48% 10.01% 
MV 10.66% 15.22% 11.84% 12.59% 12.55% 
Invasive MV 11.85% 16.12% 12.65% 13.53% 13.51% 
 
 
Table A4: APACHE III codes used for exclusion criteria. 
 



























200 Respiratory 1300 Respiratory 
300 Gastrointestinal 1400 Gastrointestinal 
400 Neurological 1500 Neurological 
500 Sepsis 1600 Trauma 
600 Trauma  1700 Renal/ Genitourinary 
700 Metabolic  1800 Gynaecological 
800 Haematology 1900 Musculoskeletal 
900 Renal disorder 2100 Haematological 
1000 Other medical disorders 2200 Metabolic 
1100 Musculoskeletal/ Skin  
disease 
  
 0 No diagnosis entered    
*Source from Australian and New Zealand Intensive Care Society (ANZICS), Centre for 
Outcome and Resource Evaluation (CORE) Adult Patient Database (APD). The details of the 






Table A5: Exclusion criteria used in clinical trial, and in simulation 
Inclusion criteria  
Actual clinical protocol Simulation method 
Patients requiring invasive MV 
Patients with PaO2/ FiO2 (PF ratio) < 300 
mmHg 
Arterial line in situ. 
Patients requiring Invasive mechanical 
ventilation 
Exclusion criteria  
Patients who are likely to be discontinued 
from MV within 24 hours. 
Exclude patient with LoMV < 1 days. 
Patients with age < 16 years. Exclude patient with age < 16 years. 
Any medical condition associated with a 
clinical suspicion of raised intracranial 
pressure and/or a measured intracranial 
pressure ≥ 20 cmH2O. 
Exclude patient with head trauma using 
APACHE III diagnostic Code 
601 - Head trauma with or without multi 
trauma 
1601 - Post operation patients: head trauma 
with or without multi trauma 
Patients who have a high spinal cord injury 
with loss of motor function and/ or have 
significant weakness from any neurological 
disease. 
 
Exclude patient using APACHE III 
diagnostic Code 
400 - Neurological non-operative 
604 - Multi trauma with spinal injury 
605 - Isolated cervical spine injury 
1500 - Post-operative: Neurological patients 
1604 - Post-operation patients: Multi trauma 
with spinal injury 
1605 - Post operation patients: isolated 
cervical spine injury 
Patients who have a barotrauma 
(pneumothorax, pneumomediastinum, 
subcutaneous emphysema or any intercostal 
catheter for the treatment of air leak). 
No action performed 
Patients who have asthma as the primary 
presenting condition or a history of significant 
chronic obstructive pulmonary disease. 
 
Exclude APACHE III diagnostic code 
206 - Chronic obstructive pulmonary disease 
209 - Asthma 
Patients who are moribund and/or not 
expected to survive for > 72 hours. 
No action performed 
Patients who have already received MV for > 
48 hours (including time spent ventilated in a 
referring unit). 
No action performed 
Lack of clinical equipoise by intensive care 
unit (ICU) medical staff managing the patient. 
No action performed 
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